Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing
Colin McGaw, Anthony J. Garrity, Gabrielle Munoz, Jeffrey R. Haswell, Sejuti Sengupta, Elise Keston-Smith, Pratyusha Hunnewell, Alexa Ornstein, Mishti Bose, Quinton N. Wessells, Noah Jakimo, Paul Yan, Huaibin Zhang, Lauren E. Alfonse, Roy Ziblat, Jason Carte, Weicheng Lu, Derek Cerchione, Brendan J. Hilbert, Shanmugapriya Sothiselvam, Winston X. Yan, David R. Cheng, David Scott, Tia DiTommaso, Shaorong Chong
Abstract
The CRISPR-Cas type V-I is a family of Cas12i-containing programmable nuclease systems guided by a short crRNA without requirement for a tracrRNA. Here we present an engineered Type V-I CRISPR system (Cas12i), ABR-001, which utilizes a tracr-less guide RNA. The compact Cas12i effector is capable of self-processing pre-crRNA and cleaving dsDNA targets, which facilitates versatile delivery options and multiplexing, respectively. We apply an unbiased mutational scanning approach to enhance initially low editing activity of Cas12i2. The engineered variant, ABR-001, exhibits broad genome editing capability in human cell lines, primary T cells, and CD34+ hematopoietic stem and progenitor cells, with both robust efficiency and high specificity. In addition, ABR-001 achieves a high level of genome editing when delivered via AAV vector to HEK293T cells. This work establishes ABR-001 as a versatile, specific, and high-performance platform for ex vivo and in vivo gene therapy.